Compound class:
Synthetic organic
Comment: The structure for tacaciclib was obtained from proposed INN list 129 (August 2023), where it is described as cyclin-dependent kinase inhibitor and antineoplastic agent. The structure is calimed in patent WO2022130304A1, for potential to treat cancer or other proliferative diseases that are mediated by CDK7 [1]. Interogation of online information suggests that this compound may be XL102 (formerly AUR102), an orally bioavailable covalent CDK7 inhibitor that was acquired by Exelixis, from Aurigene, in late 2020.
|
|